Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer

This study is a multicenter, prospective investigation aiming to evaluate the efficacy and safety of low-dose radiotherapy (15Gy/1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy concurrently with Adebrelimab, followed by Adebrelimab maintenance therapy for up to two years, in subjects with extensive-stage small cell lung cancer (ES-SCLC). Additionally, immunohistochemical detection of the expression levels of four key transcriptional proteins-YAP1, NEUROD1, ASCL1, and POU2F3-will be performed to guide the molecular subtyping of SCLC. Based on these findings, we will

Trial Details

NCT ID

NCT07583550

Phase

PHASE2

Sponsor

Jiangmen Central Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Etoposide
Cisplatin
Carboplatin
Adebrelimab
Thoracic Radiotherapy

Locations (sample)

Jiangmen, Guangdong, China|22.58333,113.08333

Key Eligibility Criteria

Age ≥18 years and ≤75 years.
Histologically or cytologically confirmed SCLC.
No prior thoracic radiotherapy or thoracic surgery.
No prior systemic anti-tumor therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →